An Open-Label, Multinational, Multicenter, Phase IIIB Study With Subcutaneus Administration Of Trastuzumab In Patient With Her2-Positive Early Breast Cancer To Evaluate Patient Satisfaction

drug protocol number
ML28851
drug sponsor
Roche
drug study
Trastuzumab SC
drug trial site
KKUH (Closed)
drug status
Terminated
drug phase